The 30% comes from.... Basically, if you analyze the impact of the Patented Medicine Prices Review Board, what they do is pick a basket of seven countries that have the highest prices to set Canada's introductory average, so it's an artificially high introductory price. Instead of taking the OECD average, say 30%—
On November 1st, 2012. See this statement in context.